These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27889115)

  • 1. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
    Reuter P; Pardo B
    Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the 'added value' of European policy on new psychoactive substances.
    Chatwin C
    Int J Drug Policy; 2017 Feb; 40():111-116. PubMed ID: 27956185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prohibition is a key driver of the new psychoactive substances (NPS) phenomenon.
    Rolles S; Kushlick D
    Addiction; 2014 Oct; 109(10):1589-90. PubMed ID: 25163705
    [No Abstract]   [Full Text] [Related]  

  • 4. A critical examination of the definition of 'psychoactive effect' in Australian drug legislation.
    Barratt MJ; Seear K; Lancaster K
    Int J Drug Policy; 2017 Feb; 40():16-25. PubMed ID: 27884504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties.
    Rychert M; Wilkins C
    Drug Test Anal; 2016 Aug; 8(8):768-78. PubMed ID: 26857892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, 'legal highs') in New Zealand.
    Rychert M; Wilkins C
    Int J Drug Policy; 2016 Nov; 37():90-97. PubMed ID: 27639994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New psychoactive substances legislation in Ireland - Perspectives from academia.
    Kavanagh PV; Power JD
    Drug Test Anal; 2014; 6(7-8):884-91. PubMed ID: 24478277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can new psychoactive substances be regulated effectively? An assessment of the British Psychoactive Substances Bill.
    Reuter P; Pardo B
    Addiction; 2017 Jan; 112(1):25-31. PubMed ID: 27220685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
    Van Hout MC; Hearne E
    Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control Measures.
    Evans-Brown M; Sedefov R
    Handb Exp Pharmacol; 2018; 252():3-49. PubMed ID: 30194542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to commentaries.
    Wilkins C
    Addiction; 2014 Oct; 109(10):1593-4. PubMed ID: 25163708
    [No Abstract]   [Full Text] [Related]  

  • 12. Worldwide legislative challenges related to psychoactive drugs.
    Negrei C; Galateanu B; Stan M; Balalau C; Dumitru MLB; Ozcagli E; Fenga C; Kovatsi L; Fragou D; Tsatsakis A
    Daru; 2017 Jun; 25(1):14. PubMed ID: 28578694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand.
    Rychert M; Wilkins C; Parker K; Witten K
    Drug Alcohol Rev; 2018 Mar; 37(3):406-413. PubMed ID: 29285812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of new psychoactive substances in Northeast Asia from 2007 to 2015.
    Lee J; Yang S; Kang Y; Han E; Feng LY; Li JH; Chung H
    Forensic Sci Int; 2017 Mar; 272():1-9. PubMed ID: 28088088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand.
    Wilkins C
    Addiction; 2014 Oct; 109(10):1580-6. PubMed ID: 24529166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlling new drugs under marketing regulations.
    Hughes B; Winstock AR
    Addiction; 2012 Nov; 107(11):1894-9. PubMed ID: 22288473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Issues with monitoring the safety of psychoactive products under a legal regulated market for new psychoactive substances ('legal highs') in New Zealand.
    Rychert M; Wilkins C; Witten K
    Drug Alcohol Rev; 2017 Sep; 36(5):589-596. PubMed ID: 28229493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical analysis of the implementation of a legal regulated market for new psychoactive substances ("legal highs") in New Zealand.
    Rychert M; Wilkins C
    Int J Drug Policy; 2018 May; 55():88-94. PubMed ID: 29524738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diverse reasons for using Novel Psychoactive Substances - A qualitative study of the users' own perspectives.
    Soussan C; Andersson M; Kjellgren A
    Int J Drug Policy; 2018 Feb; 52():71-78. PubMed ID: 29241144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To prohibit or regulate psychoactive substances: has New Zealand got the right approach?
    Rizwan SB; Vernall AJ
    BMJ; 2017 Mar; 356():j1195. PubMed ID: 28314708
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.